Lepu Biopharma Statistics
Total Valuation
Lepu Biopharma has a market cap or net worth of HKD 8.72 billion. The enterprise value is 9.10 billion.
Market Cap | 8.72B |
Enterprise Value | 9.10B |
Important Dates
The last earnings date was Wednesday, May 21, 2025.
Earnings Date | May 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Lepu Biopharma has 1.71 billion shares outstanding. The number of shares has increased by 1.87% in one year.
Current Share Class | 1.66B |
Shares Outstanding | 1.71B |
Shares Change (YoY) | +1.87% |
Shares Change (QoQ) | +2.44% |
Owned by Insiders (%) | 35.28% |
Owned by Institutions (%) | 6.16% |
Float | 651.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 22.29 |
PB Ratio | 12.02 |
P/TBV Ratio | 27.34 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -20.79 |
EV / Sales | 23.25 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -37.29 |
Financial Position
The company has a current ratio of 0.62, with a Debt / Equity ratio of 1.25.
Current Ratio | 0.62 |
Quick Ratio | 0.53 |
Debt / Equity | 1.25 |
Debt / EBITDA | n/a |
Debt / FCF | -3.71 |
Interest Coverage | -18.28 |
Financial Efficiency
Return on equity (ROE) is -54.02% and return on invested capital (ROIC) is -15.62%.
Return on Equity (ROE) | -54.02% |
Return on Assets (ROA) | -10.61% |
Return on Invested Capital (ROIC) | -15.62% |
Return on Capital Employed (ROCE) | -32.00% |
Revenue Per Employee | 785,936 |
Profits Per Employee | -879,066 |
Employee Count | 498 |
Asset Turnover | 0.16 |
Inventory Turnover | 2.87 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.78% in the last 52 weeks. The beta is -0.11, so Lepu Biopharma's price volatility has been lower than the market average.
Beta (5Y) | -0.11 |
52-Week Price Change | -0.78% |
50-Day Moving Average | 4.25 |
200-Day Moving Average | 3.30 |
Relative Strength Index (RSI) | 64.33 |
Average Volume (20 Days) | 15,076,274 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lepu Biopharma had revenue of HKD 391.40 million and -437.77 million in losses. Loss per share was -0.26.
Revenue | 391.40M |
Gross Profit | 311.77M |
Operating Income | -421.26M |
Pretax Income | -451.41M |
Net Income | -437.77M |
EBITDA | -333.82M |
EBIT | -421.26M |
Loss Per Share | -0.26 |
Balance Sheet
The company has 506.54 million in cash and 904.72 million in debt, giving a net cash position of -398.18 million or -0.23 per share.
Cash & Cash Equivalents | 506.54M |
Total Debt | 904.72M |
Net Cash | -398.18M |
Net Cash Per Share | -0.23 |
Equity (Book Value) | 725.56M |
Book Value Per Share | 0.44 |
Working Capital | -423.55M |
Cash Flow
In the last 12 months, operating cash flow was -209.00 million and capital expenditures -35.03 million, giving a free cash flow of -244.03 million.
Operating Cash Flow | -209.00M |
Capital Expenditures | -35.03M |
Free Cash Flow | -244.03M |
FCF Per Share | -0.14 |
Margins
Gross margin is 79.66%, with operating and profit margins of -107.63% and -111.85%.
Gross Margin | 79.66% |
Operating Margin | -107.63% |
Pretax Margin | -115.33% |
Profit Margin | -111.85% |
EBITDA Margin | -85.29% |
EBIT Margin | -107.63% |
FCF Margin | n/a |
Dividends & Yields
Lepu Biopharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.87% |
Shareholder Yield | n/a |
Earnings Yield | -5.02% |
FCF Yield | -2.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Lepu Biopharma has an Altman Z-Score of -0.28. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.28 |
Piotroski F-Score | n/a |